| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.25 | 5e-12 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.3 | 2e-11 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.2 | 4e-09 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-08 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.19 | 6e-08 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-07 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.16 | 6e-07 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.34 | 7e-07 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.26 | 2e-06 |